|
May 14
|
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
|
|
May 9
|
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
|
|
May 7
|
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
|
|
May 7
|
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
|
|
May 3
|
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
|
|
May 2
|
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 2
|
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
|
|
May 1
|
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
|
|
Apr 30
|
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
|
|
Apr 16
|
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
|
Apr 15
|
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
|
|
Apr 9
|
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference
|
|
Apr 7
|
When Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?
|
|
Mar 17
|
11 Oversold Biotech Stocks To Buy Right Now
|
|
Mar 8
|
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
|
|
Jan 5
|
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results
|
|
Jan 3
|
Painful week for retail investors invested in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) after 5.9% drop, institutions also suffered losses
|
|
Dec 10
|
This Small Pharma Could Be Targeted, But Would Be Fine Alone, Too
|
|
Dec 6
|
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
|
|
Dec 2
|
Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past year
|